NEW YORK (GenomeWeb) – Nuclea Biotechnologies is auctioning its assets as part of Chapter 7 bankruptcy proceedings.
Heritage Global Partners will manage the auction, set for Jan. 18, 2017. The sale will include Nuclea's intellectual property and other assets such as its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer that overexpressed the HER2/neu protein.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
